Myocardial Injury and Dysfunction Associated With COVID-19 Vaccination

COVID-19 Clinical Trial

— MIDAVAX  

Official title:

Evaluation of Myocardial Dysfunction Due to mRNA-based SARS-CoV-2 Vaccines

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05359250
• Other study ID #: 21-4055
• Secondary ID: 3UM1AI068614-14S
• Status: Recruiting
• Start date: May 12, 2021
• Est. completion date: September 2024

Study information

• Verified date: November 2023
• Source: University of Colorado, Denver
• Contact: Rachel Rosenberg, MS
• Phone: 303 724 4544
• Email: Rachel.Rosenberg[@]cuanschutz.edu
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The overall goal of the study is to investigate the characteristics and potential mechanisms responsible for myocardial injury and dysfunction in patients after COVID-19 vaccination. Cardiac damage will be assessed with cardiac MRI and endomyocardial biopsy (EmBx) histopathology. Myocardial gene expression will be measured in RNA extracted from EmBxs mRNA abundance compared to nonfailing and failing control hearts.

Description:

To determine whether there is microvascular thrombosis-associated myocardial damage and dysfunction vs. inflammation or other changes in patients who, following administration of SARS-CoV-2 mRNA vaccine, develop evidence of myocardial injury typically diagnosed as "myocarditis" based on cardiac MRI findings.

Further, the degree of inflammatory reaction vs. microthrombotic injury to cardiac myocytes from biopsied myocardial tissue will be compared with biopsied myocardial tissue from control hearts. mRNA expression of the ACE2 and ITGA5 binding targets of SARS-Cov-2 Spike protein encoded by mRNA vaccines, as well as expression of other genes that may contribute to post-vaccine pro-thrombotic and pro-inflammatory states including Coagulation Factor 3 (F3, also known as tissue factor), ACE, AGTR1 and AGT) or a dysfunctional cardiac state (NPPB as a marker of pathologic remodeling) will be examined as candidate genes. Additional, global gene expression is being measured by RNA-Seq and microarray.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 10
• Est. completion date: September 2024
• Est. primary completion date: June 30, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. age =18 years;

2. clear evidence of myocardial involvement including:

1. High Sensitivity Troponin I value of (=0.05 ng/ml (the 99% upper bound)) OR

2. an LVEF < 50% OR

3. ST-T change suggesting STEMI, NSTEMI or myopericarditis in the absence of coronary artery disease, OR

4. new onset sustained VT or VF

3. Late gadolinium enhancement or edema on cMRI consistent with myocardial injury or inflammation.

4. Documentation of vaccination with mRNA-based COVID-19 vaccine.

5. No history of COVID-19, or a negative SARS-CoV-2 PCR or other FDA approved laboratory test within 1 week of enrollment.

6. Patient and/or legally authorized representative must be competent to understand and agree with informed consent form.

Exclusion Criteria:

1. Hemodynamic instability as evidenced by escalating doses of inotropic agents or vasopressors within the prior 24 hours

2. Respiratory instability as evidenced by increasing oxygen requirements over the 24 hours prior to consent or FiO2 requirement = 60 %.

3. evidence that respiratory failure is the primary reason for myocardial dysfunction;

4. Moderate to severe pulmonary hypertension (mean PAP =35 mmHg);

5. INR >1.8 on no anticoagulation or contraindication to withdrawing anticoagulation;

6. platelets <100,000/mm3.

7. History of laboratory-confirmed SARS-CoV-2 infection as determined by polymerase chain reaction (PCR) testing or other commercial or public health assay.

8. Acute or chronic kidney disease with glomerular filtration rate < 30 ml/min.1.72m2

Related Conditions & MeSH terms

• COVID-19
• Myocardial Injury
• Vaccine Reaction

Locations

Country	Name	City	State
United States	University of Colorado Anschutz Medical Campus	Aurora	Colorado

Sponsors (3)

Lead Sponsor	Collaborator
University of Colorado, Denver	American Heart Association, National Institute of Allergy and Infectious Diseases (NIAID)

Country where clinical trial is conducted

United States, 

References & Publications (2)

Oster ME, Shay DK, Su JR, Gee J, Creech CB, Broder KR, Edwards K, Soslow JH, Dendy JM, Schlaudecker E, Lang SM, Barnett ED, Ruberg FL, Smith MJ, Campbell MJ, Lopes RD, Sperling LS, Baumblatt JA, Thompson DL, Marquez PL, Strid P, Woo J, Pugsley R, Reagan-Steiner S, DeStefano F, Shimabukuro TT. Myocarditis Cases Reported After mRNA-Based COVID-19 Vaccination in the US From December 2020 to August 2021. JAMA. 2022 Jan 25;327(4):331-340. doi: 10.1001/jama.2021.24110. — View Citation

Patone M, Mei XW, Handunnetthi L, Dixon S, Zaccardi F, Shankar-Hari M, Watkinson P, Khunti K, Harnden A, Coupland CAC, Channon KM, Mills NL, Sheikh A, Hippisley-Cox J. Risks of myocarditis, pericarditis, and cardiac arrhythmias associated with COVID-19 vaccination or SARS-CoV-2 infection. Nat Med. 2022 Feb;28(2):410-422. doi: 10.1038/s41591-021-01630-0. Epub 2021 Dec 14. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Myocardial damage	Initial clinical diagnosis of myocardial injury or myocarditis will be confirmed by cardiac MRI. Specific findings of late gadolinium enhancement and abnormal T1-signals within the myocardium consistent with acute injury, inflammation or edema will be evaluated.	clinical follow up for at least 30 days following endomyocardial biopsy
Primary	Histopathological changes assessed by light- and electron-microscopy in myocardial tissue	Determining the histopathologic changes present in the endomyocardial biopsies of patients with COVID-19 vaccine-induced myocardial injury. Assessment of the standard H&E stains will include evaluation for presence and degree of inflammation within the myocardium, presence of microvascular thrombi within vasculature, and evidence of myocardial damage. The trichrome, iron, and Congo red stains will be used to evaluate for the presence of fibrosis, iron, or amyloid, respectively. Electron microscopy will be employed to examine cardiac myocyte and small blood vessel architectures.	clinical follow up for at least 30 days following endomyocardial biopsy
Primary	Myocardial mRNA expression	Measure myocardial mRNA expression of candidate genes involved in Spike protein binding and cell entry (ACE2 and ITGA5), the renin-angiotensin system (ACE, AGT, AGTR1), initiation of coagulation (F3/TF) and pathologic myocardial remodeling (NPPB).	clinical follow up for at least 30 days following endomyocardial biopsy
Secondary	Myocardial mRNA expression of additional genes measured by both RNA-Seq and microarray.	Measure mRNA expression of additional candidate and global genes, and compare results to nonfailing and failing controls. Seven candidate genes will be measured by three platforms (qPCR, RNA-Seq and microarray), and global transcripts by RNA-Seq and microarray.	clinical follow up for at least 30 days following endomyocardial biopsy